Marinus Pharmaceuticals Announced Topline Results From Phase 3 RAISE Trial Of Intravenous Ganaxolone For Refractory Status Epilepticus, The Trial Met The First Co-primary Endpoint But Did Not Meet The Second Co-primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals announced mixed results from its Phase 3 RAISE trial of intravenous ganaxolone for refractory status epilepticus. The trial met the first co-primary endpoint but failed the second. The company will focus on its ZTALMY franchise and expects Phase 3 TrustTSC topline data in Q4 2024. Marinus projects a cash runway into Q2 2025 due to cost reduction plans and recent financing.
June 17, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Marinus Pharmaceuticals' Phase 3 RAISE trial for intravenous ganaxolone met one primary endpoint but failed the second. The company will focus on its ZTALMY franchise and expects Phase 3 TrustTSC topline data in Q4 2024. Cost reduction plans and recent financing extend cash runway into Q2 2025.
The mixed results from the Phase 3 RAISE trial are likely to have a neutral short-term impact on MRNS stock. Meeting one primary endpoint is positive, but failing the second is a setback. The company's focus on the ZTALMY franchise and extended cash runway provide some stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100